Data acquisition iEEG recordings were acquired from the FDA-approved rDBS device (NeuroPace) as reported previously 21
For instance, Xie Y et al
Optimizing The Quantity and Quality of GLP-1 Weight Loss: Evidence from a 12-Week Comparative Study GLP1 medications have changed whats possible for weight loss, but they also raise a critical question: what are people losingfat, lean mass, or both
Nausea, diarrhea, constipation, and vomiting are the most commonly reported issues with all three, and they tend to be worst during the dose-escalation phase
(Among this group, 1.9 million also had diabetes, making them already eligible for Medicare coverage of other GLP-1 drugs approved for diabetes.) Although Wegovy already had FDA approval as an anti-obesity medication, Medicare is prohibited by law from covering drugs when prescribed for obesity